127 related articles for article (PubMed ID: 38644763)
1. PD-1/PD-L1 Checkpoint Inhibition Associated Bullous Pemphigoid: A Propensity Matched Retrospective Cohort Study.
Sarkovics K; Kolodney JA; Kolodney MS
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38644763
[No Abstract] [Full Text] [Related]
2. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.
Shalata W; Weissmann S; Itzhaki Gabay S; Sheva K; Abu Saleh O; Jama AA; Yakobson A; Rouvinov K
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358869
[TBL] [Abstract][Full Text] [Related]
4. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
5. Nonbullous pemphigoid secondary to PD-1 inhibition.
Singer S; Nelson CA; Lian CG; Dewan AK; LeBoeuf NR
JAAD Case Rep; 2019 Oct; 5(10):898-903. PubMed ID: 31646161
[No Abstract] [Full Text] [Related]
6. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
Nakai K; Sato Y; Kubo S; Tsuruta D
J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513
[No Abstract] [Full Text] [Related]
8. Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
Zumelzu C; Alexandre M; Le Roux C; Weber P; Guyot A; Levy A; Aucouturier F; Mignot-Grootenboer S; Caux F; Maubec E; Prost-Squarcioni C
Front Med (Lausanne); 2018; 5():268. PubMed ID: 30320114
[TBL] [Abstract][Full Text] [Related]
9. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
11. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
12. A Systematic Review of Drug-Induced Pemphigoid.
Verheyden MJ; Bilgic A; Murrell DF
Acta Derm Venereol; 2020 Aug; 100(15):adv00224. PubMed ID: 32176310
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-induced reactivation of bullous pemphigoid.
Kaul S; Wang A; Grushchak S; Albrecht J
Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
[No Abstract] [Full Text] [Related]
14. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
15. Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy.
Hirotsu K; Chiou AS; Chiang A; Kim J; Kwong BY; Pugliese S
JAAD Case Rep; 2017 Sep; 3(5):404-406. PubMed ID: 28884139
[No Abstract] [Full Text] [Related]
16. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
Kosche C; Owen JL; Sadowsky LM; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
[TBL] [Abstract][Full Text] [Related]
17. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.
Juzot C; Sibaud V; Amatore F; Mansard S; Seta V; Jeudy G; Pham-Ledard A; Benzaquen M; Peuvrel L; Le Corre Y; Lesage C; Viguier M; Baroudjian B; Dréno B; Quéreux G
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e511-e514. PubMed ID: 33783881
[No Abstract] [Full Text] [Related]
18. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
19. Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases.
van Beek N; Weidinger A; Schneider SW; Kleinheinz A; Gläser R; Holtsche MM; von Georg A; Hammers CM; Hübner F; Lima AL; Gola D; Sadik CD; Zillikens D; Katalinic A; Schmidt E; König IR
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1197-1202. PubMed ID: 33428263
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris.
Ernst N; Friedrich M; Bieber K; Kasperkiewicz M; Gross N; Sadik CD; Zillikens D; Schmidt E; Ludwig RJ; Hartmann K
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):486-492. PubMed ID: 32596926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
